The Q1 results confirm Keros is now a pre-revenue clinical-stage biotech burning ~$6M/quarter. The stock will trade entirely on pipeline catalysts: the Phase 2 DMD trial start for rinvatercept (expected Q2 2026) and Takeda's Phase 3 plans for elritercept. Monitor for enrollment updates and regulatory feedback on the ALS trial design in H2 2026. The $281.5M cash position provides a multi-year runway, reducing near-term dilution risk.
KROS drugs
KROS drug pipeline →Price Chart
Executive Summary
Keros Therapeutics reported Q1 2026 results with a net loss of $23.7M ($1.21/share) vs net income of $148.5M ($3.66/share) in Q1 2025, driven by the absence of the large Takeda license revenue recognized last year. Total revenue collapsed to $367K from $211.2M, reflecting the non-recurring nature of the 2025 milestone. Cash burn was modest ($5.9M QoQ), and the company maintains runway into H1 2028. The key positive is Takeda's plan to advance elritercept into a Phase 3 trial in myelofibrosis, but this is a partner-driven catalyst with no near-term revenue impact.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue of $367K, down 99.8% from $211.2M in Q1 2025 due to the non-recurrence of Takeda license revenue
- Net loss of $23.7M ($1.21/share) vs net income of $148.5M ($3.66/share) in Q1 2025
- Cash and equivalents of $281.5M as of March 31, 2026, down from $287.4M at year-end 2025; runway into H1 2028
- R&D expenses fell to $16.1M from $48.7M, reflecting transition of elritercept costs to Takeda and 2025 restructuring
- Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis, a positive pipeline catalyst but partner-controlled
- Weighted-average diluted shares outstanding fell to 19.6M from 41.0M a year ago due to the 2025 share repurchase and tender offer
Financial Impact
Revenue decline of $210.9M YoY; net income swing of -$172.2M; cash burn of $5.9M in Q1
Risk Factors
- No near-term revenue stream, fully dependent on pipeline success and Takeda partnership execution
- Rinvatercept Phase 2 DMD trial initiation may slip from Q2 2026 guidance
- Takeda could deprioritize elritercept development, removing the primary value driver
- Significant share count reduction from 2025 buyback limits float and liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001664710-26-000029 |
| Document: kros-20260514.htm | 0001664710-26-000029 |
| Document: 0001664710-26-000029-index-headers.html | 0001664710-26-000029 |
| Document: 0001664710-26-000029-index.html | 0001664710-26-000029 |
| Document: 0001664710-26-000029.txt | 0001664710-26-000029 |
| 8-K Data (Synthetic) | 0001664710-26-000029 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers